The bacterial lysate Lantigen B reduces the number of acute episodes in patients with recurrent infections of the respiratory tract: The results of a double blind, placebo controlled, multicenter clinical trial

Immunology Letters

Volumn 162, Issue 2, 2014, Pages 185-193

  Braido, Fulvio ^a   Melioli, Giovanni ^a   Candoli, Piero ^b   Cavalot, Andrea ^c   Di Gioacchino, Mario ^d   Ferrero, Vittorio ^e   Incorvaia, Cristoforo ^f   Mereu, Carlo ^g   Ridolo, Erminia ^h   Rolla, Giovanni ⁱ   Rossi, Oliviero ^j   Savi, Eleonora ^k   Tubino, Libero ^l   Reggiardo, Giorgio ^m   Baiardini, Ilaria ^a   di Marco, Eddi ⁿ   Rinaldi, Gilberto ^o   Canonica, Giorgio Walter ^a   Accorsi, Carlo ^c   Bossilino, Claudia ⁱ   Bonzano, Laura ^h   DiLizia, Michela ^d   Fedrighini, Barbara ^c   Garelli, Valentina ^a   Gerace, Vincenzo ^l   Maniscalco, Sara ^g   Massaro, Ilaria ^j   Messi, Alessandro ^b   Milanese, Manlio ^g   Peveri, Silvia ^k   Penno, Arminio ^c   Pizzimenti, Stefano ⁱ   Pozzo, Tiziana ^e   Raie, Alberto ⁱ   Regina, Sergio ^e   Sclifò, Francesca ^a   more..

^a UNIVERSITY OF GENOA   (Italy)

^b Ospedale di Lugo   (Italy)

^c Ospedale S Croce Moncalieri (TO)   (Italy)

^d UNIVERSITY OF CHIETI   (Italy)

^e GRADENIGO HOSPITAL   (Italy)

^f PARKINSON INSTITUTE   (Italy)

^g SANTA CORONA HOSPITAL   (Italy)

^h UNIVERSITY OF PARMA   (Italy)

ⁱ UNIVERSITY OF TURIN   (Italy)

^j CAREGGI UNIVERSITY HOSPITAL   (Italy)

^k AUSL di Piacenza   (Italy)

^l Divisione di Cardiologia   (Italy)

^m Mediservice   (Italy)

ⁿ G GASLINI INSTITUTE   (Italy)

^o Direzione Medica Bruschettini srl   (Italy)

more..

Author keywords

Allergy; Bacterial lysates; Immune stimulant drugs; Prophylactic treatment; Recurrent respiratory tract infections

Indexed keywords

ANTIALLERGIC AGENT; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; BACTERIUM LYSATE; BRONCHODILATING AGENT; CORTICOSTEROID; LANTIGEN B; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; UNCLASSIFIED DRUG;

ABSENTEEISM; ADULT; ALLERGY; ARTICLE; BURNING MOUTH; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MOUTH DISEASE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; ODYNOPHAGIA; OROPHARYNX BURNING; PHARYNX DISEASE; PHASE 4 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT RESPIRATORY TRACT INFECTION; RESPIRATORY TRACT INFECTION; STOMATITIS; TREATMENT OUTCOME; XEROSTOMIA;

EID: 84912562005     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2014.10.026     Document Type: Article

References (23)

1. Braido F., Schenone G., Pallestrini E., Reggiardo G., Cangemi G., Canonica G.W., et al. The relationship between mucosal immunoresponse and clinical outcome in patients with recurrent upper respiratory tract infections treated with a mechanical bacterial lysate. J Biol Regul Homeost Agents 2011, 25(July-September (3)):477-485.
2. Drake C.H., Smith J.E. Salivary antibody response to oral vaccine. Lancet 1975, (September):614-615.
3. Clancy R.L., Cripps A.W., Husband A.J., Buckley D. Specific immune response in the respiratory tract after administration of an oral polyvalent bacterial vaccine. Infect Immun 1983, 39(February (2)):491-496.
4. Dirienzo W., Merli A.L., Ciprandi G., Scordamaglia A., De Gugliemi A., Marugo A., et al. Risposta anticorpale salivare e sierica ad una vaccinoterapia orale. Arch Med Intern 1984, 36(2):2-8.
5. Jannuzzi C., Campelli A., Taverna P., Piscopo R., Morandi N. Sulla validità delle vaccinazioni contro bacteri della patologia del faringe e delle prime vie aeree. Atti del convegno nazionale prevenzione, trattamento e riabilitazione dell'età evolutiva 1985.
6. Muzio M., Polentarutti N., Bosisio D., Prahladan M.K., Mantovani A. Toll-like receptors: a growing family of immune receptors that are differentially expressed and regulated by different leukocytes. J Leukoc Biol 2000, 67(April (4)):450-456.
7. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392(March (6673)):245-252.
8. Zelle-Rieser C., Ramoner R., Bartsch G., Thurnher M. A clinically approved oral vaccine against pneumotropic bacteria induces the terminal maturation of CD83+ immunostimulatory dendritic cells. Immunol Lett 2001, 76(February (1)):63-67.
9. Morandi B., Agazzi A., D'Agostino A., Antonini F., Costa G., Sabatini F., et al. A mixture of bacterial mechanical lysates is more efficient than single strain lysate and of bacterial-derived soluble products for the induction of an activating phenotype in human dendritic cells. Immunol Lett 2011, 138(July (1)):86-91.
10. Lanzilli G., Falchetti R., Cottarelli A., Macchi A., Ungheri D., Fuggetta M.P. In vivo effect of an immunostimulating bacterial lysate on human B lymphocytes. Int J Immunopathol Pharmacol 2006, 19(July-September (3)):551-559.
11. Lanzilli G., Traggiai E., Braido F., Garelli V., Folli C., Chiappori A., et al. Administration of a polyvalent mechanical bacterial lysate to elderly patients with COPD: effects on circulating T, B and NK cells. Immunol Lett 2013, 149(January (1-2)):62-67.
12. Ricci R., Palmero C., Bazurro G., Riccio A.M., Garelli V., Di Marco E., et al. The administration of a polyvalent mechanical bacterial lysate in elderly patients with COPD results in serological signs of an efficient immune response associated with a reduced number of acute episodes. Pulm Pharmacol Ther 2014, 27(February (1)):109-113.
13. Price H.C., Henley G. Trial of an oral antigen in upper respiratory tract infections in two Bristol Schools. Practitioner 1974, 213:720-726.
14. Price H.C., Henley G. Trial of an oral antigen in upper respiratory tract infections: results in the second year. Practitioner 1976, 216(March (1293)):341-346.
15. Meichen F.W., Howell R.W. Lantigen oral bacterial antigen in an industrial population. Practitioner 1981, 225(February (1352)):225-227.
16. Mora R., Salzano F.A., Mora E., Guastini L. Efficacy of a topical suspension of bacterial antigens for the management of chronic suppurative otitis media. Eur Arch Otorhinolaryngol 2012, 269(June (6)):1593-1597.
17. Pozzi E., Serra C. Efficacy of Lantigen B in the prevention of bacterial respiratory infections. Monaldi Arch Chest Dis 2004, 61(January-March (1)):19-27.
18. Mora R., Bellussi L., Passali F.M., Crippa B., Mora F., Cordone M.P., et al. Efficacy of a topical suspension of bacterial antigens for the management of recurrent eczema in children. Med Sci Monit 2004, 10(September (9)):PI99-PI103.
19. Chen A.H., Chen R.C., Zhang C.Q., Chen D., Huang S., Lin Y., et al. Efficacy of sublingual polyvalent bacterial vaccine (Lantigen B) in children with recurrent respiratory infection: a randomized double-blind controlled clinical trial. Zhonghua Er Ke Za Zhi 2004, 42(June (6)):463-464.
20. Tyrrell D.A.J., Nolan P.S., Reed S., Healy M.J.R. Trial of an oral bacterial antigen against common colds. Br J Prev Soc Med 1972, 26:129-131.
21. Roethlisberger F.J., Dickson W.J. Management and the worker 1939, Harvard University Press, Cambridge, MA.
22. Schluger N.W., Koppaka R. Lung disease in a global context. A call for public health action. Ann Am Thorac Soc 2014, 11(March (3)):407-416.
23. Bartlett J.G. A call to arms: the imperative for antimicrobial stewardship. Clin Infect Dis 2011, 53(August (Suppl. 1)):S4-S7.